Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.

Repositorio Dspace/Manakin

Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.

Mostrar el registro completo del ítem

Título: Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial fibrillation.
Autor: Domínguez, Fernando; Climent, Vicente; Zorio, Esther; Ripoll Vera, Tomás; Salazar Mendiguchía, Joel; García Pinilla, José Manuel; Urbano Moral, José Ángel; Fernández Fernández, Xusto; López Cuenca, David; Ajo Ferrer, Raquel; Sanz Sánchez, Jorge; Gómez Pérez, Yolanda; López Garrido, Miguel A.; Barriales Villa, Roberto; Gimeno, Juan Ramón; García Pavía, Pablo
Resumen: Background: Chronic anticoagulation with vitamin K antagonists (VKAs) is recommended in patients with hypertrophic cardiomyopathy (HCM) and atrial fibrillation (AF). Direct oral anticoagulants (NOACs) are an alternative to VKAs but there are limited data to support their use in HCM. We sought to describe the pattern of use, thromboembolic events, bleeding and quality of life in patients with HCM and AF treated with NOACs. Methods: Data from patients treated with NOACs (n=99) and VKA (n=433) at 9 inherited cardiac diseases units were retrospectively collected. Annual rates of embolic events, serious bleeding and death were analysed and compared. Quality of life and treatment satisfaction were evaluated with SF-36 and SAFUCA questionnaires in 80 NOAC-treated and 57 VKA-treated patients. Results: After median follow-up of 63 months (IQR:26–109), thromboembolic events (TIA/stroke and peripheral embolism) occurred in 10% of patients on oral anticoagulation. Major/clinically relevant bleeding occurred in 3.8% and the global mortality rate was 23.3%. Thromboembolic event rate was 0.62 per 100 patient-years in the NOAC group vs. 1.59 in the VKA group [subhazard ratio (SHR) 0.32;95%CI:0.04– 2.45;p=0.27]. Major/clinically relevant bleeding occurred in 0.62 per 100 person-years in the NOAC group vs. 0.60 in the VKA group (SHR 1.28;95%CI 0.18–9.30;p=0.85). Quality of life scores were similar in both groups; however, NOAC-treated patients achieved higher scores in the SAFUCA. Conclusions: HCM patients with AF on NOACs showed similar embolic and bleeding rates to those on VKA. Although quality of life was similar in both groups, the NOAC group reported higher treatment satisfaction.
Identificador universal: http://hdl.handle.net/10641/1368
Fecha: 2017


Ficheros en el ítem

Ficheros Tamaño Formato Ver
dominguez2017.pdf 928.5Kb PDF Ver/Abrir

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro completo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España Excepto si se señala otra cosa, la licencia del ítem se describe comoAtribución-NoComercial-SinDerivadas 3.0 España

Buscar en DSpace


Búsqueda avanzada

Listar

Mi cuenta

Estadísticas

Enlaces